Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Protein kinase R

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    25 result(s) found for: Protein kinase R. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2005-003495-38 Sponsor Protocol Number: PA18439 Start Date*: 2005-11-17
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A randomized, double-blind, placebo-controlled study to determine the efficacy and safety of 5 dose regimens of RO4402257 in patients with active rheumatoid arthritis (RA) on stable methotrexate (M...
    Medical condition: Rheumatoid Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) ES (Completed) DE (Prematurely Ended) GB (Completed) EE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2005-003694-25 Sponsor Protocol Number: PA18604 Start Date*: 2006-01-27
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Ensayo randomizado, doble ciego, con doble enmascaramiento, de grupos paralelos para evaluar la eficacia y seguridad de RO4402257 como monoterapia en comparación con la monoterapia de metotrexato ...
    Medical condition: Artritis Reumatoide Rheumatoid Arthritis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-012595-27 Sponsor Protocol Number: A8081007 Start Date*: 2010-01-20
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017
    Full Title: PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF PF 02341066 VERSUS STANDARD OF CARE CHEMOTHERAPY (PEMETREXED OR DOCETAXEL) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (...
    Medical condition: ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) DE (Completed) PL (Completed) ES (Completed) HU (Completed) FR (Completed) GR (Completed) IT (Completed) IE (Completed) BG (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003335-35 Sponsor Protocol Number: M13-542 Start Date*: 2016-05-03
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ...
    Medical condition: Moderately to Severely Active Rheumatoid Arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) IE (Completed) ES (Completed) DK (Completed) CZ (Completed) SE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) NO (Completed) SK (Completed) PT (Completed) LV (Completed) AT (Completed) FI (Completed) GR (Completed) FR (Completed) BG (Completed) SI (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003332-13 Sponsor Protocol Number: M13-549 Start Date*: 2016-01-12
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease...
    Medical condition: Moderately to Severely Active Rheumatoid Arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) ES (Completed) BG (Completed) CZ (Completed) DK (Completed) BE (Completed) IE (Completed) PT (Completed) GB (GB - no longer in EU/EEA) PL (Completed) LV (Completed) FI (Completed) NO (Completed) LT (Completed) HU (Completed) GR (Completed) AT (Completed) RO (Completed) HR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-006007-15 Sponsor Protocol Number: JAKAR Start Date*: 2022-09-01
    Sponsor Name:Leiden University Medical Center (LUMC)
    Full Title: Januse kinase Inhibition with Filgotinib to Silence Autoreactive B cells in Rheumatoid Arthritis
    Medical condition: patients with ACPA-positieve active RA
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004859 10003268 Arthritis rheumatoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-005462-30 Sponsor Protocol Number: MDCO-APO-14-01 Start Date*: 2016-10-26
    Sponsor Name:The Medicines Company
    Full Title: A multiple dose, dose-finding, placebo controlled, double blind, randomized trial to compare the effect of treatment on plaque burden as determined by intravascular ultrasound and evaluate the effi...
    Medical condition: acute coronary syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000064-42 Sponsor Protocol Number: MS200527-0081 Start Date*: 2016-07-27
    Sponsor Name:Merck KGaA
    Full Title: Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of M2951 in Subjects with Rheumatoid Arthritis on Stable Methotrexate Therapy
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-003376-75 Sponsor Protocol Number: M15-555 Start Date*: 2016-06-23
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 Monotherapy to Methotrexate (MTX) in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response to MTX
    Medical condition: Moderately to Severely Active Rheumatoid Arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) GR (Completed) CZ (Completed) BE (Completed) PL (Completed) HU (Completed) PT (Completed) AT (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-000169-42 Sponsor Protocol Number: KPL-404-C211 Start Date*: 2022-10-28
    Sponsor Name:Kiniksa Pharmaceuticals, Ltd.
    Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Subjects with Moderate to Severe, Active Rheumatoid Art...
    Medical condition: Rheumatoid arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) HU (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012504-13 Sponsor Protocol Number: A8081005 Start Date*: 2010-01-20
    Sponsor Name:Pfizer Inc 235 East 42nd Street, New York, NY10017
    Full Title: PHASE 2, OPEN-LABEL SINGLE ARM STUDY OF THE EFFICACY AND SAFETY OF PF 02341066 IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION INVOLVING THE ANAP...
    Medical condition: metastatic non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) DE (Completed) ES (Completed) HU (Completed) PL (Completed) GR (Completed) IT (Completed) FR (Completed) IE (Completed) BG (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002916-34 Sponsor Protocol Number: ITCC-054/AAML1921 Start Date*: 2016-06-13
    Sponsor Name:Erasmus MC
    Full Title: A Phase I/II study of Bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ Chronic Myeloid Leukemia, study ITCC-054/COG AAML1921
    Medical condition: Chronic Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009700 CML LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) IE (Completed) DE (Ongoing) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned) DK (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000868-18 Sponsor Protocol Number: 202018 Start Date*: 2019-12-02
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A 24-week, phase 3, multicentre, randomised, double-blind, efficacy and safety study, comparing GSK3196165 with placebo and with sarilumab, in combination with conventional synthetic DMARDs, in par...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) PL (Completed) LT (Completed) ES (Completed) BE (Completed) CZ (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002379-40 Sponsor Protocol Number: CAFQ056B2278 Start Date*: 2012-01-09
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label study to evaluate the long-term safety and tolerability of AFQ056 in adolescent patients with Fragile X Syndrome
    Medical condition: Fragile X syndrome
    Disease: Version SOC Term Classification Code Term Level
    16.1 10010331 - Congenital, familial and genetic disorders 10017324 Fragile X syndrome PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) Outside EU/EEA GB (Prematurely Ended) ES (Temporarily Halted) DK (Prematurely Ended) IT (Completed) FR (Completed) NL (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004391-39 Sponsor Protocol Number: CTKI258A2107 Start Date*: 2008-04-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase I/II multi-center, open label study of TKI258 administered orally on an intermittent schedule in adult patients with advanced or metastatic Renal Cell Cancer (RCC)
    Medical condition: advanced or metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003697-70 Sponsor Protocol Number: VIB4920.P2.S3 Start Date*: 2020-02-21
    Sponsor Name:Viela Bio, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of VIB4920 in Patients with Rheumatoid Arthritis (RA)
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-001862-13 Sponsor Protocol Number: AB19001 Start Date*: 2020-03-12
    Sponsor Name:ABScience
    Full Title: A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo ...
    Medical condition: patients suffering from Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) FR (Trial now transitioned) BE (Prematurely Ended) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) PT (Ongoing) ES (Restarted) DK (Trial now transitioned) PL (Ongoing) IE (Prematurely Ended) IT (Prematurely Ended) NO (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000933-37 Sponsor Protocol Number: M15-925 Start Date*: 2016-11-24
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Into...
    Medical condition: Moderately to Severely Active Rheumatoid Arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) LV (Completed) PT (Completed) SE (Completed) ES (Ongoing) CZ (Completed) BE (Completed) NL (Completed) SK (Prematurely Ended) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001265-16 Sponsor Protocol Number: COEB071X2103 Start Date*: 2013-09-30
    Sponsor Name:Novartis Farma S.p.A
    Full Title: An Open-Label, Single-arm, Phase Ib/II study of AEB071 (a Protein Kinase C Inhibitor) and Everolimus (mTOR inhibitor) in Patients with CD79-mutant or ABC subtype Diffuse Large B-Cell Lymphoma
    Medical condition: Diffuse Large B-cell Lymphoma (DLBCL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003418-41 Sponsor Protocol Number: NAV3-32 Start Date*: 2020-05-18
    Sponsor Name:Navidea Biopharmaceuticals Ltd
    Full Title: A Comparison of Tc 99m Tilmanocept Quantitative Imaging with Immunohistochemical (IHC) Analysis of CD206 Expression in Synovial Tissue from Subjects Clinically Diagnosed with Rheumatoid Arthritis (RA)
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 12:34:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA